Periodic Reporting for period 1 - PnuBioVax (PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.)
Okres sprawozdawczy: 2019-05-01 do 2019-09-30
The prevention of pneumococcal diseases is a global challenge that has been partially addressed through vaccination. Some of the societal issues associated with pneumococcal diseases are that (1) they are a major cause of mortality in the young and elderly, (2) current vaccines have limited efficacy and coverage, (3) vaccination is not always accessible and (4) pneumococcal disease presents an ecoomic burden. ImmBio is developing next-generation vaccines against serious infectious disease targets, starting with a vaccine against pneumococcal disease, utilising its proprietary technology platforms to directly induce immunity via dendritic cells.
During the Feasibility Study, ImmBio has completed a full analysis of the technical and business potential of its new vaccine. During the project the company has expanded its knowledge primarily with regards to the required clinical validation and regulatory approval for European market launch.
PnuBioVax™ (PBV) is a next-generation, multi-antigen, serotype-independent and adjuvant-free prophylactic vaccine against invasive pneumococcal disease. Although most competing vaccines are effective against the variants they specifically target, there are significant issues associated with them; i) high production costs, ii) low breadth of protection, iii) promotion of antibiotic resistance and, iv) their efficacy depends on the prevalence of the targeted variants in the different geographical regions. Immbio intends to bring to market a clinically validated vaccine against pneumococcal disease that will increase prevention and be more widely accessible thanks to its lower cost of production.